Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.

Article  PubMed  Google Scholar 

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Cancer Genome Atlas Research Network, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

Article  PubMed  Google Scholar 

O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan X, Fu H, Xie N, Guo H, Fu T, Shan Y. Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Aging (Albany NY). 2021;13(19):22830–42.

Article  CAS  PubMed  Google Scholar 

Li Y, Wei J, Sun Y, Zhou W, Ma X, Guo J, et al. DLGAP5 regulates the proliferation, migration, invasion, and cell cycle of breast cancer cells via the JAK2/STAT3 signaling axis. Int J Mol Sci. 2023;24(21):15819.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan K, Ye J, Liu Z, Ren Y, He W, Xu J, et al. Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020;39(1):9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen M, Zeng J, Chen S, Li J, Wu H, Dong X, et al. SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway. Aging (Albany NY). 2020;12(11):10896–911.

Article  CAS  PubMed  Google Scholar 

Zhang K, Che S, Pan C, Su Z, Zheng S, Yang S, et al. The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating the IL6/JAK2 pathway. J Cell Mol Med. 2018;22(7):3679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Hu F, Li G, Li G, Yang X, Liu L, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 2018;9(2):25.

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Wang X, Wang L, Mei Y, Yun Y, Yao X, et al. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling. Int J Med Sci. 2022;19(6):965–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laczmanska I, Michalowska D, Jedryka M, Blomka D, Semeniuk M, Czykalko E, et al. Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer. Pathol Res Pract. 2023;242: 154315.

Article  CAS  PubMed  Google Scholar 

James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8.

Article  CAS  PubMed  Google Scholar 

Lin Q, Chen Z, Shi W, Lv Z, Wan X, Gao K. JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway. Cell Commun Signal. 2022;20(1):177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, et al. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012;72(19):5035–47.

Article  CAS  PubMed  Google Scholar 

Kannan A, Krishnan A, Ali M, Subramaniam S, Halagowder D, Sivasithamparam ND. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer. 2014;50(1):204–15.

Article  CAS  PubMed  Google Scholar 

May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E, et al. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2005;24(6):1011–20.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Ma X, Dong L, Liu X, Ou K, Yang L. POLE/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res. 2022;41(1):216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113(3):365–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, et al. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013;3:3042.

Article  PubMed  PubMed Central  Google Scholar 

Dvořáček L, Marková J, Holoubek A, Grebeňová D, Kundrát D, Kuželová K, et al. A novel germline hyperactivating JAK2 mutation L604F. Ann Hematol. 2023;102(10):2725–34.

Article  PubMed  PubMed Central  Google Scholar 

Percy MJ, McMullin MF. The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol. 2005;23(3–4):91–3.

Article  CAS  PubMed  Google Scholar 

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372–83.

Article  CAS  PubMed  Google Scholar 

Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, et al. Ruxolitinib. Recent Results Cancer Res. 2018;212:119–32.

Article  CAS  PubMed  Google Scholar 

Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, et al. A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2020;26(10):2346–53.

Article  CAS  PubMed  Google Scholar 

Lynce F, Williams JT, Regan MM, Bunnell CA, Freedman RA, Tolaney SM, et al. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2011;87(5):673–9.

Article  Google Scholar 

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018;36(4):683–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, et al. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med. 2018;7(11):5382–93.

Article  CAS  PubMed  PubMed Central  Google Scholar